Giotrif in non‑small cell lung cancer therapy – case report

04/2017

MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

 

SUMMARY

The activating epidermal growth factor receptor mutation is present in almost 50% of patients with advanced non-small cell lung cancer, who are of Asian ethnicity1 compared with only 12% in the Caucasian population.2 These molecular alterations predict sensitivity to first and second generation epidermal growth factor receptor tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib. Response rate and progression-free survival with epidermal growth factor receptor tyrosine kinase inhibitors are superior to standard first-line platinum doublet chemotherapy, making them the standard of care.

 

KEY WORDS

non-small cell lung cancer, epidermal growth factor receptor mutations, afatinib, gefitinib, erlotinib

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM